
MEI Pharma Inc (NASDAQ:MEIP) shares are plunging in Thursday's after-hours session after the company provided an investor update following a recent meeting with the U.S. Food and Drug Administration.
During the meeting, the FDA informed MEI Pharma that a randomized trial would now be needed to adequately assess drug efficacy and safety of PI3K inhibitor drug candidates, including zandelisib.